ImmusanT Grabs $12M as Celiac Vaccine Hits Critical Proving Ground

ImmusanT is trying to prove that a vaccine it’s developing can help celiac patients eat gluten without getting sick. Today, the Cambridge, MA-based company got enough dough to (Read more...)